Anavex Life Sciences Corp. President and CEO Terrie Kellmeyer filed a statement of changes in beneficial ownership on November 6, 2026, disclosing the acquisition of 200,000 stock options on November 3, 2026.

Key Highlights

  • Reporting person: Terrie Kellmeyer, President and CEO and Director of Anavex Life Sciences Corp. (NASDAQ:AVXL)
  • Security acquired: 200,000 Stock Options (Right to Buy) in Common Stock, with an exercise price of $1.20 per share
  • Transaction date: November 3, 2026, with the transaction coded as an acquisition (A)
  • Expiration date: November 2, 2036, giving the options a ten-year term from the transaction date
  • Vesting schedule: Options vest in three substantially equal annual installments beginning May 4, 2027
  • Grant basis: Options were granted pursuant to the terms of Kellmeyer's employment agreement with the issuer, dated May 4, 2026
  • Price of derivative security: $0, as reported in Table II of the filing

Anavex Life Sciences CEO Option Grant Details and Vesting Terms

According to the filing, Terrie Kellmeyer, who serves as both President and CEO and as a Director of Anavex Life Sciences Corp., acquired 200,000 Stock Options (Right to Buy) on November 3, 2026. The options carry an exercise price of $1.20 per share and are exercisable into shares of Common Stock. The filing reports a price of $0 for the derivative security itself, indicating no cash consideration was paid by Kellmeyer to receive the grant. Following the reported transaction, Kellmeyer beneficially owns 200,000 derivative securities directly.

The filing states that the option grant was made "pursuant to the terms of the Reporting Person's employment agreement with the Issuer, dated May 4, 2026." Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol AVXL. The options are set to vest in three substantially equal annual installments beginning on May 4, 2027, and they expire on November 2, 2036. No shares of non-derivative Common Stock were reported as acquired or disposed of in Table I of the filing.

The filing was signed by Terrie Kellmeyer and dated November 6, 2026. The ownership form for the 200,000 options is listed as direct (D). No deemed execution date was indicated, and the filing was made by one reporting person with no indication of a Rule 10b5-1 plan election checked on the form.

What Was Disclosed

The filing disclosed that Anavex Life Sciences Corp. President and CEO Terrie Kellmeyer acquired 200,000 stock options with a $1.20 exercise price on November 3, 2026, granted under a May 4, 2026, employment agreement, vesting over three annual installments starting May 4, 2027.